Search Follow us

Transgene (TNG)

Business description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Restructuring to focus on R&D

QuickView | Pharmaceutical & healthcare | 09/11/2015

Transgene is a biopharmaceutical company focused on the discovery, development and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its pipeline includes two Phase III-ready candidates, TG4010 (lung cancer) and Pexa-Vec (liver cancer), and TG1050 (hepatitis B), which is due to start Phase I in Q415. In June, Transgene announced a restructuring programme to focus the business on R&D, with plans to close its pharmaceutical development and bio-manufacturing capabilities (c €1.7m of revenue in 2014). Our valuation and financials are under review, pending further details.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€189.3m
Last close€3.040
High / Low (52 weeks)€3.5 / €2.5
Stock market listingEU
Forecast net debt (€m)45.2
Forecast gearing ratio (%)1863
SectorPharmaceutical & healthcare

Price performance

Relative *(2.8)6.6(11.7)

* % Relative to local index

Company news